Alder Biopharmaceuticals (NASDAQ:ALDR) was downgraded by stock analysts at ValuEngine from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday.
A number of other research firms have also recently commented on ALDR. Piper Jaffray Companies started coverage on shares of Alder Biopharmaceuticals in a research note on Monday, August 6th. They set an “overweight” rating and a $28.00 target price for the company. Morgan Stanley started coverage on shares of Alder Biopharmaceuticals in a research note on Monday, September 10th. They set an “underweight” rating and a $19.00 target price for the company. Zacks Investment Research cut shares of Alder Biopharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, October 8th. BMO Capital Markets boosted their target price on shares of Alder Biopharmaceuticals from $21.00 to $23.00 and gave the stock a “buy” rating in a research note on Wednesday, August 8th. Finally, BidaskClub lowered shares of Alder Biopharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, August 28th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and nine have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $21.75.
Shares of ALDR stock traded down $0.88 on Thursday, reaching $12.83. 578,400 shares of the company were exchanged, compared to its average volume of 1,194,229. The stock has a market capitalization of $1.14 billion, a P/E ratio of -2.59 and a beta of 2.59. The company has a quick ratio of 10.88, a current ratio of 10.88 and a debt-to-equity ratio of 0.73. Alder Biopharmaceuticals has a 1 year low of $9.55 and a 1 year high of $20.87.
Alder Biopharmaceuticals (NASDAQ:ALDR) last released its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($1.04) EPS for the quarter, topping analysts’ consensus estimates of ($1.05) by $0.01. On average, analysts expect that Alder Biopharmaceuticals will post -4.73 earnings per share for the current year.
In other Alder Biopharmaceuticals news, Director Jeffrey T. L. Smith sold 5,040 shares of the business’s stock in a transaction dated Tuesday, September 4th. The shares were sold at an average price of $18.00, for a total value of $90,720.00. Following the transaction, the director now directly owns 5,871 shares in the company, valued at approximately $105,678. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider John A. Latham sold 24,999 shares of the business’s stock in a transaction dated Monday, October 1st. The shares were sold at an average price of $15.44, for a total transaction of $385,984.56. Following the completion of the transaction, the insider now owns 261,878 shares in the company, valued at $4,043,396.32. The disclosure for this sale can be found here. Insiders have sold 90,117 shares of company stock worth $1,591,970 over the last 90 days. 17.40% of the stock is currently owned by company insiders.
Large investors have recently bought and sold shares of the business. American Century Companies Inc. boosted its holdings in Alder Biopharmaceuticals by 56.7% in the 2nd quarter. American Century Companies Inc. now owns 173,235 shares of the biopharmaceutical company’s stock valued at $2,737,000 after purchasing an additional 62,704 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in Alder Biopharmaceuticals in the 2nd quarter valued at about $1,956,000. TD Asset Management Inc. boosted its holdings in Alder Biopharmaceuticals by 79.1% in the 2nd quarter. TD Asset Management Inc. now owns 83,300 shares of the biopharmaceutical company’s stock valued at $1,316,000 after purchasing an additional 36,800 shares during the last quarter. Fox Run Management L.L.C. acquired a new position in Alder Biopharmaceuticals in the 2nd quarter valued at about $198,000. Finally, Brown Advisory Inc. boosted its holdings in Alder Biopharmaceuticals by 1.2% in the 2nd quarter. Brown Advisory Inc. now owns 1,078,596 shares of the biopharmaceutical company’s stock valued at $17,042,000 after purchasing an additional 12,432 shares during the last quarter.
Alder Biopharmaceuticals Company Profile
Alder BioPharmaceuticals, Inc operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine and other serious neurological or inflammatory conditions in the United States, Australia, and Ireland.
Recommended Story: What are retained earnings?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Alder Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.